authID Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that authID Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.04M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $886.5K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $190.3K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $527.4K | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $613.5K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $2.14M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $2.55M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $3.83M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $2.30M | Mar 8, 2019 |
| FY2013 | Dec 31, 2012 | $7.70M | Jun 30, 2014 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2012 | $1.19M | Jun 30, 2014 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.93M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.28M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($19.40M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($24.23M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($17.67M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($11.30M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($10.50M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($10.03M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($17.48M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($9.85M) | Mar 15, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($18.15M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.68M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($10.75M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($22.27M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($17.09M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($9.01M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($10.09M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($9.32M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($12.01M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($13.57M) | Mar 15, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.69M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.24M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.59M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $6.27M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $2.88M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.16M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $1.61M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $894.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $222.1K | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $340.3K | Mar 15, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.99M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.62M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($8.37M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($12.79M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($8.76M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($4.67M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($6.06M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($5.95M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($6.54M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($3.81M) | Mar 15, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $7.0K | Mar 20, 2024 |
| FY2021 | Dec 31, 2021 | $90.0K | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $27.4K | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $59.1K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $13.2K | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $23.6K | Mar 15, 2018 |
| FY2016 | Dec 31, 2015 | $16.3K | Jul 12, 2017 |
| FY2015 | Dec 31, 2014 | $419.6K | Nov 2, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.98M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $14.47M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $15.41M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $9.37M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $13.83M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $13.87M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $13.54M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $18.14M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $17.03M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $12.55M | Mar 15, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.36M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $2.96M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $2.21M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $9.09M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $2.93M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $9.29M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.26M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $3.55M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $4.09M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $25.80M | Mar 15, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.62M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.52M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $13.20M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $283.5K | Mar 13, 2025 |
| FY2023 | Dec 31, 2021 | $10.90M | Mar 20, 2024 |
| FY2022 | Dec 31, 2020 | $4.58M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $8.28M | Mar 22, 2022 |
| FY2020 | Dec 31, 2018 | $14.59M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $12.94M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | ($13.25M) | Mar 8, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.18M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.18M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $4.18M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $4.18M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.18M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | $5.22M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $6.74M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $6.74M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $6.74M | Mar 15, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($191.74M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($173.81M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($159.53M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($140.13M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($115.90M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($98.23M) | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | ($86.94M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($76.44M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | ($66.41M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($48.93M) | Mar 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $3.77M | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $567.1K | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | $4.97M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $4.41M | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $689.1K | Mar 8, 2019 |
| FY2017 | Dec 31, 2015 | $349.9K | Mar 15, 2018 |
| FY2016 | Dec 31, 2014 | $159.3K | Jul 12, 2017 |
| FY2015 | Dec 31, 2013 | $5.3K | Nov 2, 2016 |
| FY2014 | Dec 31, 2012 | $17.6K | Mar 31, 2015 |
| FY2013 | Dec 31, 2011 | $4.4K | Jun 30, 2014 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $135.4K | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $276.1K | Mar 30, 2023 |
| FY2019 | Dec 31, 2019 | $2.01M | Mar 30, 2020 |
| FY2018 | Dec 31, 2018 | $2.00M | Mar 8, 2019 |
| FY2017 | Dec 31, 2017 | $3.00M | Mar 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 8, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 8, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.13M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 10.92M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 9.45M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 3.18M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 23.29M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 19.64M | Mar 22, 2022 |
| FY2020 | Dec 31, 2019 | 518.13M | Mar 8, 2021 |
| FY2018 | Dec 31, 2018 | 478.95M | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | 403.31M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 234.70M | Mar 15, 2018 |